Cohance Lifesciences share price
NSE: COHANCEBSE: 543064Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹453.85.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹17,211 Cr428th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 5 Aug 2026
- 162.0
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹21 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 134.9
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 12 May 2026
- 4.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 5 Aug 2026
- 3.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹21 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 4.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 5 Aug 2026
- 3.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 12 May 2026
- 0.04
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 5,73,70251.1% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 5 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹422 Crdown 31.80%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹45 CrQuarter to Mar 2026: ₹8.31 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −10.7%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 13 Nov | Dec 2024Filed 13 Feb | Mar 2025Filed 13 Jun | Jun 2025Filed 9 Sep | Sep 2025Filed 17 Jul | Dec 2025Filed 12 Feb | Mar 2026Filed 12 May | Jun 2026Filed 5 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 258 | 307 | 402 | 549 | 556 | 545 | 619 | 422 |
| Net profit | 82 | 83 | 39 | 46 | 66 | 29 | 8 | −45 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 31.8% | 27.1% | 9.6% | 8.4% | 11.9% | 5.3% | 1.3% | −10.7% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 91% of 1,240 trading days over the last 5 years.
At or below today's level on 13% of 1,114 trading days over the last 5 years.
At or below today's level on 79% of 1,114 trading days over the last 5 years.
At or below today's level on 62% of 1,240 trading days over the last 5 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −73.8% | −55.4% | −41.3% | 0.0% |
| 3 years | −13.9% | −33.8% | +30.0% | 0.0% |
| 5 years | −9.1% | −19.9% | +13.0% | 0.4% |
Mutual funds holding it
106 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 47 of the 58 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 3
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 3
- AddedAdded. Funds that held more shares than at the end of the month before.
- 23
- CutCut. Funds that held fewer shares than at the end of the month before.
- 35
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 42
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 9
| Fund | |||
|---|---|---|---|
 ICICI Prudential Healthcare FundICICI Prudential Mutual Fund | 62,66,692 | 4.06% | ₹278.2 Cr |
 SBI Multi Asset Allocation FundSBI Mutual Fund | 52,00,000 | 1.10% | ₹230.9 Cr |
 Invesco India Contra FundInvesco Mutual Fund | 43,93,667 | 1.01% | ₹195.1 Cr |
 HDFC Balanced Advantage FundHDFC Mutual Fund | 41,43,548 | 0.18% | ₹184.0 Cr |
 DSP Healthcare FundDSP Mutual Fund | 32,02,999 | 3.79% | ₹142.2 Cr |
 Bandhan Small Cap FundBandhan Mutual Fund | 31,27,757 | 0.39% | ₹138.9 Cr |
| SBI Balanced Advantage FundSBI Mutual Fund | 30,00,000 | 0.33% | ₹133.2 Cr |
| DSP Aggressive Hybrid FundDSP Mutual Fund | 23,47,265 | 0.92% | ₹104.2 Cr |
| SBI Healthcare Opportunities FundSBI Mutual Fund | 22,00,000 | 1.66% | ₹97.7 Cr |
| SBI MNC FundSBI Mutual Fund | 22,00,000 | 1.53% | ₹97.7 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Cohance Lifesciences in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Piramal PharmaPPLPHARMA | 25,438 | – | 3.1 | 29.4 | +0.8% | −419.8% | −3.9% | 1.1% | 0.00% |
 Neuland LaboratoriesNEULANDLAB | 24,204 | 48.6 | 12.9 | 31.5 | +78.3% | +182.6% | 29.3% | 32.1% | 0.18% |
 Rubicon ResearchRUBICON | 23,578 | 81.8 | 18.3 | 52.2 | – | – | 22.4% | 25.8% | 0.11% |
 Granules IndiaGRANULES | 21,679 | 32.7 | – | – | +24.8% | +38.1% | 15.1% | 15.1% | 0.22% |
 Shilpa MedicareSHILPAMED | 16,904 | 56.9 | 6.5 | 36.6 | +27.9% | +167.6% | 12.0% | 10.9% | 0.07% |
 Caplin Point LaboratoriesCAPLIPOINT | 16,890 | 25.4 | 4.7 | 20.4 | +15.0% | +17.7% | 20.7% | 19.8% | 0.36% |
 PfizerPFIZER | 16,525 | 22.5 | 3.9 | 14.2 | +10.7% | −9.1% | 17.5% | 21.0% | 2.08% |
 Natco PharmaNATCOPHARM | 15,534 | 13.6 | – | – | −20.7% | −32.6% | 13.6% | 8.6% | 0.57% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 9 Sep 2022 | Interim | ₹1.00 |
| 9 Sep 2022 | Special | ₹5.00 |
| 13 May 2022 | Interim | ₹1.00 |
| 13 May 2022 | Special | ₹1.00 |
| 15 Feb 2022 | Interim | ₹1.00 |
| 15 Feb 2022 | Special | ₹2.00 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
9 Oct · General Updates
6 Oct · General Updates
Sep 2026
21 Sep · Updates
Cohance Lifesciences share price by year
Each calendar year to 2025.Cohance Lifesciences share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 528.60 | −53.6% | 1,230.00 | 525.70 |
| 2024 | 1,138.75 | +57.5% | 1,334.20 | 610.45 |
| 2023 | 722.80 | +46.0% | 722.80 | 464.90 |
| 2022 | 494.90 | +0.3% | 621.15 | 395.05 |
| 2021 | 493.25 | +9.1% | 579.05 | 439.40 |
| 2020 | 452.30 | – | 476.60 | 95.43 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 453.00 | 454.00 | 437.40 | 449.85 | 446.93 | 5,73,702 | 51.1% |
| 22 Oct 2026 | 456.70 | 461.40 | 451.05 | 453.85 | 455.62 | 4,11,587 | 68.7% |
| 21 Oct 2026 | 464.90 | 470.75 | 453.00 | 461.80 | 463.62 | 7,30,876 | 27.4% |
| 19 Oct 2026 | 468.00 | 468.00 | 456.00 | 457.70 | 460.69 | 3,54,458 | 53.2% |
| 16 Oct 2026 | 460.45 | 467.35 | 458.10 | 464.05 | 464.25 | 7,63,452 | 73.1% |
| 15 Oct 2026 | 446.30 | 471.55 | 444.15 | 459.95 | 463.24 | 26,18,808 | 22.5% |
| 14 Oct 2026 | 436.10 | 448.80 | 432.25 | 445.60 | 441.53 | 4,66,904 | 46.2% |
| 13 Oct 2026 | 447.50 | 447.70 | 427.50 | 437.35 | 434.75 | 4,35,818 | 44.7% |
| 12 Oct 2026 | 446.60 | 449.80 | 441.35 | 444.45 | 445.42 | 2,80,792 | 48.5% |
| 9 Oct 2026 | 444.90 | 445.30 | 434.25 | 441.00 | 440.20 | 4,60,250 | 47.0% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 25 Sep 2020 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
About Cohance Lifesciences
Cohance Lifesciences is a contract development and manufacturing organisation, known as a CDMO: a company that develops and makes medicines or their ingredients for other drug companies. It serves pharmaceutical innovators, biotechnology companies and generic pharmaceutical customers. It is headquartered in Hyderabad, Telangana, and its equity shares are listed on the National Stock Exchange of India and BSE.
Its business is organised into Pharma CDMO, API+ and Speciality Chemicals, supported by capabilities in small molecules, antibody-drug conjugates and oligonucleotides. API+ covers active pharmaceutical ingredients and formulations, from intermediates and APIs through pellets and finished dosage forms. Speciality Chemicals has two verticals, AgChem CDMO and Performance Chemicals. Its platform combines research, process development, analytical capabilities, high-containment chemistry and commercial-scale manufacturing. The antibody-drug conjugate platform connects payload and linker chemistry in India with the bioconjugation and analytics of NJ Bio in the United States. Through Sapala Organics, the company brings capabilities in oligonucleotide building blocks such as modified nucleosides and phosphoramidites.
The company runs 13 manufacturing plants. Avra, one of the businesses brought together in the platform, adds specialised chemistry and advanced intermediates. Its manufacturing network spans Gujarat, Andhra Pradesh and Telangana in India, and Princeton, New Jersey, in the United States. It serves customers across North America, Europe, Japan and other international markets.
Its present form follows an amalgamation of two companies, effective 1 May 2025. In July 2024 it acquired a 67.5% stake in Sapala Organics.
- Legal name
- Cohance Lifesciences Limited
- NSE symbol
- COHANCE
- BSE code
- 543064
- ISIN
- INE03QK01018
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Mar 2020
- Face value
- ₹1
- Former symbols
- SUVENPHAR
- CIN
- L24299MH2018PLC422236
- Corporate identity number, the registrar of companies' code for it